Aldeyra Therapeutics, Inc. , a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will.
Submitted a new drug application (NDA) for troriluzole in Spinocerebellar Ataxia Type 3 (SCA3) to U.S. FDA in 2Q2023, marking the team s fourth NDA in.
Biohaven Pharma (BHVN) Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.